[PDF][PDF] The role of intermittent androgen deprivation in prostate cancer.
L Boccon-Gibod, P Hammerer, S Madersbacher… - BJU …, 2007 - academia.edu
L Boccon-Gibod, P Hammerer, S Madersbacher, N Mottet, T Prayer-Galetti, U Tunn
BJU international, 2007•academia.eduGeneral health-related QoL (HRQoL) and IAD with maximum androgen blockade (MAB) was
studied in 250 men with locally advanced or metastatic disease [16]. Hormonal therapy was
stopped after 9 months if the PSA level was< 4 ng/mL and restarted when the PSA level rose
to> 20 ng/mL. QoL was assessed every 3 months for 30 months using the European
Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-
PR25 module. The results showed
studied in 250 men with locally advanced or metastatic disease [16]. Hormonal therapy was
stopped after 9 months if the PSA level was< 4 ng/mL and restarted when the PSA level rose
to> 20 ng/mL. QoL was assessed every 3 months for 30 months using the European
Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-
PR25 module. The results showed
General health-related QoL (HRQoL) and IAD with maximum androgen blockade (MAB) was studied in 250 men with locally advanced or metastatic disease [16]. Hormonal therapy was stopped after 9 months if the PSA level was< 4 ng/mL and restarted when the PSA level rose to> 20 ng/mL. QoL was assessed every 3 months for 30 months using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-PR25 module. The results showed
academia.edu